Adrenal Gland Diseases

Classic CAH: New Approaches to Glucocorticoid Dosing

Endocrinology specialists are re-evaluating glucocorticoid dosing strategies for classic congenital adrenal hyperplasia (CAH), focusing on individualised regimens to balance androgen control and minimise adverse effects.

Low Alkaline Phosphatase: Recognizing Clinical Consequences

Low alkaline phosphatase (ALP) is often overlooked, but its clinical consequences, particularly hypophosphatasia, warrant increased diagnostic vigilance.

XLH Adults: Osteomalacia Persists Despite Conventional Therapy

Adults with X-linked hypophosphatemia (XLH) frequently experience persistent osteomalacia, even with conventional phosphate and active vitamin D treatment.

Desmopressin Dosing Refined for Central Diabetes Insipidus

New insights into desmopressin administration for central diabetes insipidus (CDI) aim to optimise efficacy and minimise hyponatremia risk.

Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives

New perspectives on hypoparathyroidism treatment from patients, care partners, and HCPs highlight unmet needs and treatment goals.

Hypercortisolism: Emerging Diagnostic and Management Insights

New evidence presented at Endo 2026 refines our understanding of hypercortisolism, impacting diagnostic strategies and therapeutic approaches.

Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps

Cushing's syndrome presents a diagnostic challenge, often leading to significant delays in treatment initiation and suboptimal patient outcomes.

Korlym® for Cushing's Syndrome: Patient Experience, Side Effects and 2026 Clinical Data

Patient-reported outcomes from Endo 2026 show Korlym® (mifepristone) cuts weight gain, fatigue and mood disturbances in Cushing's syndrome. Covers mechanism of cortisol receptor blockade, side effect profile, and how it compares to relacorilant.

Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome

A novel steroidogenesis inhibitor presented at ENDO 2026 offers a targeted approach to endogenous Cushing's syndrome by reducing cortisol overproduction.